News
The FDA has partially reversed course on its push to halt shipments of a controversial gene therapy made by Sarepta ...
Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular ...
On Monday, the FDA said Sarepta may resume treating ambulatory Duchenne patients with Elevidys. The recommendation comes just ...
The U.S. Food and Drug Administration said on Monday it is recommending the removal of the hold placed on Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results